Pharmafile Logo
Pharmafocus logo
Advanced Search

Tagrisso

Showing 12 posts of 27 posts found.

astrazeneca_plaque

AstraZeneca’s Tagrisso beats standard of care in halting NSCLC

September 11, 2017
Research and Development, Sales and Marketing AstraZeneca, ESMO, NSCLC, Tagrisso, non-small cell cell cancer, pharma, pharmaceutical

AstraZeneca has revealed new data at the European Society of Medical Oncology (ESMO) on the efficacy of Tagrisso (osimertinib) in …

News
astrazeneca_building_white

AZ’s Tagrisso continues successes with EU approval

April 26, 2017
Research and Development, Sales and Marketing AstraZeneca, EU, European Commission, NSCLC, Tagrisso

More good news for AstraZeneca’s Tagrisso (osimertinib), as the company announces that the European Commission has granted the drug full …

News
astrazeneca_sign_sky

AstraZeneca ends month with two pieces of news

March 31, 2017
Medical Communications, Sales and Marketing AstraZeneca, Tagrisso, TerSera Therapeutics, Zoladex

AstraZeneca has ended the month with more positive news on Tagrisso, that had previously been approved in China under its …

News
astrazeneca_logo_building

AstraZeneca’s medicine approved under China’s Priority Review

March 27, 2017
Sales and Marketing AstraZeneca, Tagrisso, lung cancer

AstraZeneca has been boosted by the news that its drug, Tagrisso, has become its first drug to be approved under …

News
astrazeneca_sign_sky

AZ lung cancer drug cuts disease progression by 70%

December 7, 2016
Research and Development AstraZeneca, Tagrisso

AstraZeneca is touting its cancer drug Tagrisso (osimertinib) as a potential new standard of care for epidermal growth factor receptor …

News
astrazeneca_sign_sky

AstraZeneca’s wins major drug approval by NICE

October 4, 2016
Manufacturing and Production AstraZeneca, Cancer Drug Fund, NHS, Tagrisso

AstraZeneca’s Tagrisso (osimertinib) has successfully received endorsement of Britain’s Cancer Drugs Fund that has a reserve of £340 million to …

News
download

Hanmi Pharma shares crash after shock contract termination

September 30, 2016
Manufacturing and Production, Medical Communications, Research and Development Boehringer Ingelheim, Genentech, Germany, HM61713, Hanmi Pharmaceutical, Tagrisso, south korea

News broke on 29 September that Hanmi Pharma, South Korea’s leading drug maker, had signed a $910 million deal with …

News
astrazeneca-sign

AstraZeneca presents positive Phase III results for lung cancer drug Tagrisso

July 18, 2016
Manufacturing and Production, Research and Development AstraZeneca, Tagrisso

AstraZeneca has presented results from the latest Phase III trial evaluating Tagrisso (osimertinib) as a second line treatment for patients …

News

Chi-Med to get $10 million milestone from AstraZeneca after initiation of expanded Phase II trials in NSCLC

June 20, 2016
Research and Development, Sales and Marketing AstraZeneca, Chi-Med, Iressa, Tagrisso, drug trial, lung cancer

Hutchison China MediTech (Nasdaq: HCM) on Monday said it is expanding Phase II trials in non-small cell lung cancer to …

News
takeda_research_centre

Japanese approval for AZ lung cancer drug

March 29, 2016
Manufacturing and Production, Sales and Marketing AstraZeneca, Tagrisso, lung cancer

AstraZeneca’s Tagrisso (osimertinib) has been approved in Japan for the treatment of a specific form of clung cancer. Japanese regulator, …

News
AZ sign

AstraZeneca’s Tagrisso gets EU lung cancer sign-off

February 4, 2016
Sales and Marketing AstraZeneca, European Commission, NSCLC, Tagrisso, non-small cell lung cancer, osimertinib

The European Commission (EC) has granted conditional marketing authorisation to AstraZeneca’s Tagrisso to treat locally advanced or metastatic non-small cell …

News
az_pacal_soriot

AstraZeneca earns ‘speedy’ FDA approval for lung cancer drug

November 13, 2015
AZD9291, AstraZeneca, Tagrisso, lung cancer

The FDA has approved AstraZeneca’s new lung cancer drug Tagrisso, in a record two and half years from development, under …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025